Leflunomide for chronic musculoskeletal graft versus host disease following allogeneic hematopoietic stem cell transplant

[1]  M. Murad,et al.  Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  A. Bonda,et al.  Leflunomide: Is It the Game Changer in Musculoskeletal Chronic Graft Versus Host Disease? , 2018, Indian Journal of Hematology and Blood Transfusion.

[3]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[4]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  Bruce R. Blazar,et al.  Advances in graft-versus-host disease biology and therapy , 2012, Nature Reviews Immunology.

[6]  N. Leca.  Leflunomide use in renal transplantation , 2009, Current opinion in organ transplantation.

[7]  A. Gabrielli,et al.  Imatinib for refractory chronic graft-versus-host disease with fibrotic features. , 2009, Blood.

[8]  James W. Williams,et al.  Leflunomide in solid organ transplantation and polyoma virus infection. , 2006, Advances in experimental medicine and biology.

[9]  K. H. Langer,et al.  Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide , 1994, Annals of Hematology.

[10]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  Dayer Jm,et al.  Leflunomide: mode of action in the treatment of rheumatoid arthritis , 2000, Annals of the rheumatic diseases.

[12]  H. Schorlemmer,et al.  Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease. , 1997, Transplantation proceedings.

[13]  M. Waer.  The use of leflunomide in transplantation immunology. , 1996, Transplant immunology.

[14]  R. Morris,et al.  Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. , 1995, Immunology letters.